Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Phenanthroline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.64 |
| ▸ | LMNA | P02545 | 4/20 | 0.64 |
| ▸ | HSP90AA1 | P07900 | 4/20 | 0.64 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.64 |
| ▸ | CCR1 | P32246 | 3/20 | 0.64 |
| ▸ | CCR5 | P51681 | 3/20 | 0.64 |
| ▸ | CCR8 | P51685 | 3/20 | 0.64 |
| ▸ | MAPT | P10636 | 2/20 | 0.64 |
| ▸ | HTT | P42858 | 2/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.64 |
| ▸ | MMP2 | P08253 | 2/20 | 0.64 |
| ▸ | TSHR | P16473 | 2/20 | 0.64 |
| ▸ | GMNN | O75496 | 1/20 | 0.64 |
| ▸ | TP53 | P04637 | 1/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.64 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.64 |
| ▸ | MMP9 | P14780 | 1/20 | 0.64 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.64 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.64 |
| ▸ | MMP8 | P22894 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phenanthroline SCHEMBL16192743 | 1.00 | KDM4E (0.64) | KDM4ELMNAHSP90AA1TDP1CCR1 | |
| Phenanthroline SCHEMBL29278214 | 0.96 | KDM4E (0.64) | KDM4ELMNAHSP90AA1TDP1CCR1 | |
| Phenanthroline SCHEMBL29188565 | 0.96 | KDM4E (0.64) | KDM4ELMNAHSP90AA1TDP1CCR1 | |
| Phenanthroline SCHEMBL28227266 | 0.96 | KDM4E (0.64) | KDM4ELMNAHSP90AA1TDP1CCR1 | |
| Phenanthroline SCHEMBL28097109 | 0.90 | LMNA (0.73) | KDM4ELMNAHSP90AA1TDP1CCR1 | |
| Phenanthroline SCHEMBL22401704 | 0.88 | LMNA (0.70) | KDM4ELMNAHSP90AA1TDP1CCR1 | |
| Phenanthroline SCHEMBL4881417 | 0.88 | LMNA (0.70) | KDM4ELMNAHSP90AA1TDP1CCR1 | |
| Acetic Acid SCHEMBL8883463 | 0.86 | HSP90AA1 (0.52) | KDM4ELMNAHSP90AA1TDP1CCR1 | |
| Acetic Acid SCHEMBL8883458 | 0.86 | KDM4E (0.52) | KDM4ELMNAHSP90AA1TDP1CCR1 | |
| Phenanthroline SCHEMBL29521774 | 0.86 | LMNA (0.67) | KDM4ELMNAHSP90AA1TDP1CCR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025068206-A1 | PERFUME COMPOSITIONS | GIVAUDAN SA (CH) | 2025-04-03 | — | — | WO | disclosed |
| CN-109715593-B | Method for removing or recovering 2-alkoxyethanol and method for producing (2-alkoxyethyl) vinyl ether | 丸善石油化学株式会社 | 2022-05-31 | — | — | CN | disclosed |
| US-11247961-B2 | Me 1 hod for removing or collecting 2-alkoxyethanol, and method for producing (2-alkoxyethyl) vinyl ether | MARUZEN PETROCHEMICAL CO., LTD. (JP) | 2022-02-15 | — | — | US | disclosed |
| EP-3514133-B1 | METHOD FOR REMOVING OR COLLECTING 2-ALKOXYETHANOL, AND METHOD FOR PRODUCING (2-ALKOXYETHYL) VINYL ETHER | MARUZEN PETROCHEM CO LTD (JP) | 2020-11-25 | — | — | EP | disclosed |
| EP-3514133-A1 | METHOD FOR REMOVING OR COLLECTING 2-ALKOXYETHANOL, AND METHOD FOR PRODUCING (2-ALKOXYETHYL) VINYL ETHER | Maruzen Petrochemical Co., Ltd. (JP) | 2019-07-24 | — | — | EP | disclosed |
| US-20190210949-A1 | METHOD FOR REMOVING OR COLLECTING 2-ALKOXYETHANOL, AND METHOD FOR PRODUCING (2-ALKOXYETHYL) VINYL ETHER | MARUZEN PETROCHEMICAL CO., LTD. (JP) | 2019-07-11 | — | — | US | disclosed |
| EP-3245191-A1 | QUINOLINES AND PROCESS FOR THE PREPARATION THEREOF | Council of Scientific & Industrial Research (IN) | 2017-11-22 | — | — | EP | disclosed |
| WO-2016113759-A1 | QUINOLINES AND PROCESS FOR THE PREPARATION THEREOF | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2016-07-21 | — | — | WO | disclosed |
| EP-2256170-B1 | Tunable fluorescent UV curable gel inks containing fluorescent monomers for food packaging applications | XEROX CORP (US) | 2014-12-24 | — | — | EP | disclosed |
| US-8334026-B2 | Tunable fluorescent UV curable gel inks containing fluorescent monomers for food packaging applications | XEROX CORPORATION (US) | 2012-12-18 | — | — | US | disclosed |
| US-8039663-B2 | Acrylate resins with the dimethanocyclopenta naphthalene in the backbone; reducing cure-induced shrinkage; semiconductor packages and microelectronic devices | DESIGNER MOLECULES, INC. (US) | 2011-10-18 | — | — | US | disclosed |
| US-20100304040-A1 | TUNABLE FLUORESCENT UV CURABLE GEL INKS CONTAINING FLUORESCENT MONOMERS FOR FOOD PACKAGING APPLICATIONS | XEROX CORPORATION (US) | 2010-12-02 | — | — | US | disclosed |
| EP-2256170-A1 | Tunable fluorescent UV curable gel inks containing fluorescent monomers for food packaging applications | Xerox Corporation (US) | 2010-12-01 | — | — | EP | disclosed |
| US-20100249465-A1 | PROCESS FOR PRODUCTION OF HIGH-PURITY VINYL ETHER | MARUZEN PETROCHEMICAL CO., LTD. (JP) | 2010-09-30 | — | — | US | disclosed |
| US-20080257493-A1 | MONOMERS DERIVED FROM PENTACYCLOPENTADECANE DIMETHANOL | DESIGNER MOLECULES, INC. | 2008-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080257493-A1 | MONOMERS DERIVED FROM PENTACYCLOPENTADECANE DIMETHANOL | TELO2, MSMO1, TMT1A | KDM4E 920/4885LMNA 4137/4885HSP90AA1 3259/4885 |
| US-20100249465-A1 | PROCESS FOR PRODUCTION OF HIGH-PURITY VINYL ETHER | ADH1A, ADH1C, VMP1 | KDM4E 821/4885LMNA 3597/4885HSP90AA1 1097/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.